SERPINA1 and alpha 1-antitrypsin deficiency: This cell therapy holds the promise of addressing both liver and lung diseases associated with AATD by ameliorating the gain of function toxicity of Z-AAT in the liver via replacing diseased cells and addressing the loss of function in the lung via restoring normal AAT protein in the serum.